Mahmut Gok1, Hakki Cetinkaya2, Tugba Kandemir3, Erdem Karahan3, İzzet Burak Tuncer3, Cengiz Bukrek3, Gulizar Sahin2. 1. Nephrology Department, Sultan Abdulhamid Han Training Hospital, Istanbul, Turkey. mahmut_gok@yahoo.com.tr. 2. Nephrology Department, Sultan Abdulhamid Han Training Hospital, Istanbul, Turkey. 3. Internal Medicine Department, Sultan Abdulhamid Han Training Hospital, Istanbul, Turkey.
Abstract
PURPOSE: The recent outbreak of COVID-19 rapidly spread worldwide. Comorbid diseases are determinants of the severity of COVID-19 infection and mortality. The aim of this study was to explore the potential association between chronic kidney disease (CKD) and the severity of COVID-19 infection. METHODS: The study included 609 consecutive adult patients (male: 54.52%, mean age: 59.23 ± 15.55 years) hospitalized with the diagnosis of COVID-19 in a tertiary level hospital. Data were collected from the electronic health records of the hospital. The patients were separated into two groups: Group I included COVID-19-positive patients with CKD stage 1-2, and Group II included COVID-19-positive with CKD stage 3-5. The relationships were examined between CKD stage, laboratory parameters and mortality. RESULTS: Significant differences were determined between the groups in respect of the inflammation parameters and the parameters used in prognosis. In Group II, statistically significantly higher rates were determined of comorbid diseases [hypertension (p < 0.001) and diabetes mellitus (p < 0.001), acute kidney injury (AKI), which was found to be associated with mortality (p < 0.001), and mortality (p < 0.001)]. In multivariate regression analysis, CKD stage 3-5, AKI, male gender, hypertension, DM and malignancy were found to be significant independent variables increasing mortality. CONCLUSION: The prevelance of CKD stage 3-5 on admission is associated with a high risk of in-hospital mortality in patients with COVID-19. Close follow-up can be recommended for patients with a reduced glomerular filtration rate (GFR).
PURPOSE: The recent outbreak of COVID-19 rapidly spread worldwide. Comorbid diseases are determinants of the severity of COVID-19 infection and mortality. The aim of this study was to explore the potential association between chronic kidney disease (CKD) and the severity of COVID-19 infection. METHODS: The study included 609 consecutive adult patients (male: 54.52%, mean age: 59.23 ± 15.55 years) hospitalized with the diagnosis of COVID-19 in a tertiary level hospital. Data were collected from the electronic health records of the hospital. The patients were separated into two groups: Group I included COVID-19-positive patients with CKD stage 1-2, and Group II included COVID-19-positive with CKD stage 3-5. The relationships were examined between CKD stage, laboratory parameters and mortality. RESULTS: Significant differences were determined between the groups in respect of the inflammation parameters and the parameters used in prognosis. In Group II, statistically significantly higher rates were determined of comorbid diseases [hypertension (p < 0.001) and diabetes mellitus (p < 0.001), acute kidney injury (AKI), which was found to be associated with mortality (p < 0.001), and mortality (p < 0.001)]. In multivariate regression analysis, CKD stage 3-5, AKI, male gender, hypertension, DM and malignancy were found to be significant independent variables increasing mortality. CONCLUSION: The prevelance of CKD stage 3-5 on admission is associated with a high risk of in-hospital mortality in patients with COVID-19. Close follow-up can be recommended for patients with a reduced glomerular filtration rate (GFR).
Authors: Christopher M Booth; Larissa M Matukas; George A Tomlinson; Anita R Rachlis; David B Rose; Hy A Dwosh; Sharon L Walmsley; Tony Mazzulli; Monica Avendano; Peter Derkach; Issa E Ephtimios; Ian Kitai; Barbara D Mederski; Steven B Shadowitz; Wayne L Gold; Laura A Hawryluck; Elizabeth Rea; Jordan S Chenkin; David W Cescon; Susan M Poutanen; Allan S Detsky Journal: JAMA Date: 2003-05-06 Impact factor: 56.272
Authors: Anand Kumar; Ryan Zarychanski; Ruxandra Pinto; Deborah J Cook; John Marshall; Jacques Lacroix; Tom Stelfox; Sean Bagshaw; Karen Choong; Francois Lamontagne; Alexis F Turgeon; Stephen Lapinsky; Stéphane P Ahern; Orla Smith; Faisal Siddiqui; Philippe Jouvet; Kosar Khwaja; Lauralyn McIntyre; Kusum Menon; Jamie Hutchison; David Hornstein; Ari Joffe; Francois Lauzier; Jeffrey Singh; Tim Karachi; Kim Wiebe; Kendiss Olafson; Clare Ramsey; Sat Sharma; Peter Dodek; Maureen Meade; Richard Hall; Robert A Fowler Journal: JAMA Date: 2009-10-12 Impact factor: 56.272
Authors: Musa A Garbati; Shamsudeen F Fagbo; Vicky J Fang; Leila Skakni; Mercy Joseph; Tariq A Wani; Benjamin J Cowling; Malik Peiris; Ahmed Hakawi Journal: PLoS One Date: 2016-11-03 Impact factor: 3.240
Authors: Kwok Hong Chu; Wai Kay Tsang; Colin S Tang; Man Fai Lam; Fernand M Lai; Ka Fai To; Ka Shun Fung; Hon Lok Tang; Wing Wa Yan; Hilda W H Chan; Thomas S T Lai; Kwok Lung Tong; Kar Neng Lai Journal: Kidney Int Date: 2005-02 Impact factor: 10.612
Authors: Khalid Aziz Ansari; Marwan Jabr Alwazzeh; Feras Ahmed Alkuwaiti; Faraz Ahmed Farooqi; Noor Al Khathlan; Hussain Almutawah; Mustafa Alahmed; Hussain Alfaraj; Ahmed Aljarrash; Jaffar Almadhary; Sarah Alwarthan; Ahmed Mohammed Alsahlawi; Abdullah Bandar Almashouf; Moammer Alqasim; Elaf Alkuwaiti Journal: Int J Gen Med Date: 2022-02-16